In Vivo Differentiation of Endogenous Bone Marrow-Derived Cells into Insulin-Producing Cells Using Four Soluble...

Area of Science:

• Endocrinology
• Cell Biology
• Regenerative Medicine

Background:

• Bone marrow mononucleated cells (BMNCs) can be differentiated into insulin-producing cells (IPCs) in vitro.
• Previous studies showed in vitro differentiation and therapeutic potential of these IPCs in diabetic models.
• The in vivo regenerative capacity of endogenous BMNCs induced by these factors remained unclear.

Purpose of the Study:

• To investigate the in vivo effect of four soluble factors on BMNC differentiation into IPCs in diabetic mice.
• To assess the therapeutic efficacy of these factors in improving glycemic control and beta-cell function in vivo.
• To track the fate of endogenous BMNCs and their contribution to IPC regeneration.

Main Methods:

• Diabetic mice were orally administered a combination of putrescine, glucosamine, nicotinamide, and a STAT3 inhibitor (BP-1-102).
• Treatment involved administration for 5 days, with a second dose 2 weeks later, followed by 45-55 days of monitoring.
• Glucose tolerance tests, glucose-stimulated insulin secretion assays, and pancreatic insulin content measurements were performed.
• Chimeric mice (BMNCs from insulin promoter luciferase/GFP transgenic donors) were used to trace endogenous BMNC differentiation.

Main Results:

• Oral administration of the factors significantly lowered blood glucose levels in diabetic mice.
• Improved glucose tolerance and enhanced glucose-stimulated insulin secretion were observed.
• Immunohistochemical analysis confirmed the presence of newly formed IPCs within the pancreas.
• Chimeric mouse studies indicated that endogenous BMNCs contributed to the formation of these pancreatic IPCs.

Conclusions:

• The studied soluble factors can induce in vivo differentiation of endogenous BMNCs into functional IPCs in diabetic mice.
• These factors demonstrate therapeutic potential for beta-cell regeneration and improving glycemic control in diabetes.
• The findings support the development of novel regenerative strategies for type 1 and type 2 diabetes treatment.